ArticleChemical & biomedical imaging2025
Albumin Encapsulation of Cyanine Dye for High-Performance NIR-II Imaging-Guided Photodynamic Therapy.
Article in Chemical & biomedical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Endogenous Albumin-Mediated Disassembly of Phthalocyanine Nanoparticles for Tumor-Selective Imaging and Sonodynamic Therapy.Chemical & biomedical imaging · 2026Article
- Recent advances of cyanine dyes in tumor theranostics: molecular modification, delivery strategies, and synergistic mechanisms.RSC advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Albumin encapsulation is a powerful strategy for drug delivery, yet its potential has not been fully explored for photodynamic therapy (PDT) agents. Cl-containing near-infrared (NIR) cyanine dyes are intrinsically PDT agents and tend to covalently bind with albumin; however, their PDT efficiency in tumors is largely compromised due to limited accumulation of the complex (size less than 10 nm) to the tumor site. To maximize their PDT effect while retaining sufficient NIR brightness for imaging-guided PDT, we developed a DTT-promoted encapsulation strategy to enhance singlet oxygen release for Cl-containing dyes. By disrupting disulfide bonds in albumin, the protein shell is loosened, increasing size while maintaining singlet oxygen release, partial brightness, and photostability. In vivo experiments reveal the rapid tumor accumulation of IR-6B3@DTT-HSA, enabling flexible treatment timing. This strategy enhances targeted delivery and PDT efficacy, paving the way for broader applications in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.